Specialty European Pharma

European speciality pharmaceutical company with a portfolio of urology products

SEP acquired and licensed several products for the European specialty urology and urogynaecology market. SEP sold a number of brands including Mitem®/Mitocin for bladder cancer and Regurin® for overactive bladder through its own sales force at the time of its acquisition.

CEO  Patrick Banks

Advent Contact  Shahzad Malik   I   Kaasim Mahmood

Advent founded SEP in 2006. SEP was acquired by Juno/ Aspire Pharmaceuticals in 2016.
Exited Investments
10 May 2010 in Press Release, SEP

SEP, the Pan-European Specialty Urology Company, acquires Mitem

Press Release.   Speciality European Pharma Limited (SEP), the pan European urology focused specialty pharmaceutical company, is pleased to announce its acquisition of the product Mitem® from Curasan AG.  Mitem…
Read More
6 July 2009 in Press Release, SEP

SEP Signs REGURIN® Deal

Press Release.   LONDON, June 18 /PRNewswire Speciality Urology Company Gains Exclusive UK Distribution Rights   Speciality European Pharma Limited (SEP), the UK based, urology focused, specialty pharmaceutical company, is…
Read More
14 August 2008 in Press Release, SEP

SEP, the specialty urology company, closes a $15M series B financing

Press Release.   Speciality European Pharma Limited (SEP), the UK based, urology focused, specialty pharmaceutical company, is pleased to announce the successful completion of a €15M series B financing led…
Read More
2 February 2008 in Press Release, SEP

Speciality European Pharma launches Plenaxis in Germany

Press Release.   Plenaxis® is the first GnRH antagonist, a new class of hormone treatment which gives physicians added control of prostate cancer.   London, 25 February. Speciality European Pharma…
Read More